Ipsen has been given accelerated approval by the FDA for Iqirvo, which becomes the first dual PPAR alpha/delta agonist ... for non-alcoholic steatohepatitis (NASH), a much larger population ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback